---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-151009"
form_type: "8-K"
ticker: null
cik: "0001840574"
company_name: "Verve Therapeutics, Inc."
filed_at: "2024-05-31T23:59:59+00:00"
generated_at: "2026-06-01T07:14:23.035757+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Verve Therapeutics appoints Troy Lister as CSO; Andrew Bellinger to resign effective June 21, 2024

## Summary
- Troy Lister, Ph.D., appointed Chief Scientific Officer effective June 21, 2024, succeeding Andrew Bellinger.
- Andrew Bellinger resigns as CSO on June 21, 2024; will provide advisory services under an Advisor Agreement.
- Bellinger receives 12 months base salary continuation, a $153,765 bonus (67% of target), and limited equity vesting.
- Advisor Agreement pays Bellinger $200/hour; cannot be terminated for convenience before two-year anniversary.
- Bellinger subject to non-compete for one year after advisor termination; non-disclosure obligations continue.

## SEC filing metadata
- accession: 0001193125-24-151009
- form_type: 8-K
- cik: 0001840574
- company_name: Verve Therapeutics, Inc.
- filed_at: 2024-05-31T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840574/000119312524151009/0001193125-24-151009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840574/000119312524151009/d797150d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-151009
- JSON: https://secwatch.observer/filing/0001193125-24-151009.json
- Plain text: https://secwatch.observer/filing/0001193125-24-151009.txt

## Key facts
- Executive change
  Andrew Bellinger resigned as Chief Scientific Officer at Verve Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Scientific Officer
  source text: Andrew Bellinger, M.D., Ph.D., who will resign as the Company's Chief Scientific Officer on the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840574/000119312524151009/0001193125-24-151009-index.htm
- Executive change
  Troy Lister was appointed as Chief Scientific Officer at Verve Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Scientific Officer
  source text: appointed Troy Lister, Ph.D., as Chief Scientific Officer of the Company, effective June 21, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840574/000119312524151009/0001193125-24-151009-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.